COMMUNIQUÉS West-GlobeNewswire

Fortrea to Participate in Jefferies Global Healthcare Conference
27/10/2026
DURHAM, N.C., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (“CRO”), today announced that CEO Anshul Thakral, CFO Jason Knoblauch, and SVP of Investor [...]
Cullinan Therapeutics Advances Velinotamig into Global Clinical Development for Autoimmune Cytopenias Following IND Clearance by the U.S. FDA
27/10/2026
Global regulatory clearances in the U.S. and Australia support initiation of a Phase 1b/2a study in relapsing and refractory ITP and wAIHA Study expands immunology portfolio into autoimmune cytopenias, evaluating a [...]
Mammogen and MammoLink Partner to Advance a New Model for Community-Based Breast Cancer Detection
27/10/2026
MammoLink joins Mammogen’s KATELYN-ERIN trial, expanding community access to a prospective study evaluating blood-based RNA biology for breast cancer detection NEWPORT BEACH, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- [...]
Cellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More Than Eight Years in Heavily Pretreated DLBCL Patient Treated with Iopofosine I 131
27/10/2026
Durable Complete Response Achieved with Single Administration of Iopofosine I 131 Provides Additional Clinical Support for the Differentiated Mechanism of Action of Iopofosine I 131 and its Potential Utility Across a [...]
Peptide Stacks: Kylo Peptides Brings Wolverine, GLOW and KLOW Into One Research Stack Line
27/10/2026
Sheridan, Wyoming, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Kylo Peptides [ https://kylopeptides.com/ ] has combined its Wolverine, GLOW, and KLOW peptide stacks into a single research stack line in its catalog. The company [...]
Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio Execution
27/10/2026
– ARCALYST ® (rilonacept) Q3 2026 net product revenue of $286.0 million, representing ~58% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $1.045 - $1.050 billion – – KPL-387 pivotal [...]
InflaRx Announces November Investor Events
27/10/2026
Jena, Germany, Oct. 27, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its events calendar [...]
Artiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK®
27/10/2026
Company halting further development of AlloNK® (AB-101), including the planned phase 3 pivotal trial Updated deep B cell depletion and clinical response data is consistent with previously reported findings; however, [...]
Medicus Pharma to Present at BioFuture and Global Biotechnology Summit
27/10/2026
Company’s Executive Chairman and CEO to Speak on Cancer Therapeutics Spotlight Panel at BioFuture in NYC and Deliver Keynote Address at Global Biotechnology Summit in Abu Dhabi PHILADELPHIA, Oct. 27, 2026 (GLOBE [...]
Cerenome to Present Interim Clinical Update on the ReSPECT-LM Trial of Multiple REYOBIQ™ Doses in Leptomeningeal Metastases
27/10/2026
Company to provide latest clinical trial data and highlight evolving approaches to leptomeningeal metastases diagnosis and treatment in a company sponsored symposium 2026 SNO Annual Meeting to be held on November 12-15 [...]
Wave Life Sciences Reports Third Quarter 2026 Financial Results and Provides Business Update
27/10/2026
Planning underway for registrational trial of WVE-006 (RNA editing) in AATD, with an interim analysis for potential accelerated approval based on AATD biomarkers Advancing WVE-007 (INHBE siRNA) across treatment settings [...]
Harvard Bioscience Schedules Third Quarter 2026 Earnings Conference Call for November 10, 2026 at 8:00 AM ET
27/10/2026
HOLLISTON, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended September 30, 2026, before the market opens on November 10, 2026, and [...]
Trevi Therapeutics to Participate in Stifel's 2026 Healthcare Conference
27/10/2026
Fireside chat with management on Wednesday, November 11, 2026, at 10:00 a.m. ET NEW HAVEN, Conn., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company [...]
Meet Patel's Passion Farms Reports 20% Year-Over-Year Growth Across Multi-State Operations
27/10/2026
Houston-based wholesaler reports a 20% revenue increase for the first nine months of 2026, matching the 20% annual growth it recorded in 2024 and 2025 HOUSTON, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Passion Farms , a Houston [...]
Firefly Neuroscience (NASDAQ: AIFF) Strengthens Non-Invasive Brain-Computer Interface Growth Strategy with Commercially Available Versus Platform
27/10/2026
– Firefly’s AI foundation model, being built on more than 200,000 standardized EEG/ERP brain scans, bolsters its long-term BCI growth opportunity – – With over 3,000 Versus headsets shipped, the platform generates [...]
Pharming Group reports third quarter 2026 financial results; strong revenue growth, Joenja APDS expansion and CVID topline data in November
27/10/2026
Third quarter 2026 total revenues increased by 21% to US$117.6 million, compared to third quarter 2025, exceeding market expectations RUCONEST® revenue increased by 14% to US$93.8 million, compared to third quarter 2025 [...]
Novartis delivered sales growth and core margin expansion in Q3; raised FY core operating income guidance
27/10/2026
Ad hoc announcement pursuant to Art. 53 LR Third quarter Q3 net sales grew +4% (cc ¹ , +4% USD), with core operating income ¹ +10% (cc, +11% USD) Sales growth driven by priority brands including Kisqali (+37% cc), [...]
Basilea raises full-year guidance 2026 and financial target for “Agenda 2030” and provides updates on late-stage clinical programs
27/10/2026
2026 operating profit expected to reach CHF 115 million (previously CHF 70 million) driven by higher than expected Cresemba and Zevtera-related revenue of CHF 250 million (previously CHF 210 million) Cumulative cash [...]
Idorsia seeks US label update for QUVIVIQ daytime functioning benefits – first patients enrolled in Dari-Dream
27/10/2026
Building on established clinical evidence, Dari-Dream is designed to further characterize the impact of QUVIVIQ on daytime functioning and support its inclusion in the US prescribing information. Allschwil, Switzerland [...]

Pages